Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 4/2013

01-12-2013 | Quality of Care in Osteoporosis (SL Silverman, Section Editor)

Prevention and Treatment of Bone Changes Associated with Exposure to Glucocorticoids

Authors: Amy H. Warriner, Kenneth G. Saag

Published in: Current Osteoporosis Reports | Issue 4/2013

Login to get access

Abstract

Rheumatologic diseases are associated with a proinflammatory state, which is thought to lead to many of the bone changes seen in treatment-naive patients. However, glucocorticoids remain a common treatment option for rheumatologic diseases and are known to have a negative impact on bone through direct effects on bone cells and indirect effects on calcium absorption. Despite the anti-inflammatory effect of glucocorticoids, fracture risk rises within the first 3 months of treatment. As such, osteoporosis prevention and treatment needs to be considered in all patients started on chronic glucocorticoids (≥3 months of treatment). For very low risk patients, conservative management with non-pharmacologic strategies may be appropriate. For the moderate to high fracture risk patients treated with glucocorticoids, pharmacologic treatment with 1 of the 4 approved medications should be considered. The challenge of educating physicians and patients of the risks of glucocorticoid induced osteoporosis remain.
Literature
1.
Adler RA, Curtis JR, Saag K, Weinstein RS. Glucocorticoid-induced osteoporosis. 3rd ed. San Diego: Elsevier-Academic Press; 2008.
2.
Cascao R, Moura RA, Perpetuo I, et al. Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R196.PubMedCrossRef
3.
Kim KW, Kim HR, Park JY, et al. Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum. 2012;64(4):1015–23.PubMedCrossRef
4.
Xu S, Wang Y, Lu J, Xu J. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. Rheumatol Int. 2012;32(11):3397–403.PubMedCrossRef
5.
Walsh NC, Reinwald S, Manning CA, et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res. 2009;24(9):1572–85.PubMedCrossRef
6.
Carmona-Fernandes D, Santos MJ, Perpetuo IP, Fonseca JE, Canhao H. Soluble receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients. Arthritis Res Ther. 2011;13(5):R175.PubMedCrossRef
7.
• Tang X, Griffith J, Qin L, et al. SLE disease per se contributes to deterioration in bone mineral density, microstructure and bone strength. Lupus. 2013;22(11):1162–8. Describes evidence for proinflammatory state associated with untreated SLE and bone changes.PubMedCrossRef
8.
• Weiss RJ, Wick MC, Ackermann PW, Montgomery SM. Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases – a case-control study with 53,108 patients with fracture. J Rheumatol. 2010;37(11):2247–50. Evaluates fracture incidence among patients with rheumatologic and inflammatory disorders compared to an unaffected control population.PubMedCrossRef
9.
Im CH, Kang EH, Ki JY, et al. Receptor activator of nuclear factor kappa B ligand-mediated osteoclastogenesis is elevated in ankylosing spondylitis. Clin Exp Rheumatol. 2009;27(4):620–5.PubMed
10.
Taylan A, Sari I, Akinci B, et al. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskeletal Disorders. 2012;13:191.PubMedCrossRef
11.
Kang KY, Ju JH, Park SH, Kim HY. The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis. Rheumatology (Oxford). 2013;52(4):718–26.PubMedCrossRef
12.
Barnabe C, Hanley DA. Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Semin Arthritis Rheum. 2009;39(2):116–22.PubMedCrossRef
13.
• Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. The New England journal of medicine. 2011;365(1):62–70. In depth review of the pathophysiology of the current understanding of glucocorticoid induced osteoporosis.CrossRef
14.
LoCascio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner. 1990;8(1):39–51.PubMedCrossRef
15.
• Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53–8. IOM report on calcium and vitamin D recommended daily intake.PubMedCrossRef
16.
• Moyer VA. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;158(9):691–6. USPSTF recommendations for calcium and vitamin D intake, more conservative recommendations than those from the IOM.PubMed
17.
• Sanfelix-Gimeno G, Sanfelix-Genoves J, Rodriguez-Bernal CL, Peiro S, Hurtado I. Prevalence, determinants and inappropriateness of calcium supplementation among men and women in a Spanish Mediterranean area. Cross-sectional data from the ESOSVAL cohort. J Bone Miner Res. 2013. Study revealing excessive or inappropriate calcium recommendations in a Spanish cohort.
18.
Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515–26.PubMedCrossRef
19.
Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–97.PubMedCrossRef
20.
• Deal CL. Recent recommendations on steroid-induced osteoporosis: more targeted, but more complicated. Cleve Clin J Med. 2013;80(2):117–25. Reviews the American College of Rheumatology guidelines for treatment of glucocorticoid induced osteoporosis.PubMedCrossRef
21.
• Lekamwasam S, Adachi JD, Agnusdei D, et al. An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Arch Osteoporos. 2012;7(1–2):25–30. Appendix for the 2012 International Osteoporosis Foundation and European Calcified Tissue Society guidelines for glucocorticoid induced osteoporosis.PubMedCrossRef
22.
• Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013. Updated recommendations for management of GIOP in patients on higher doses of glucocorticoids.
23.
van Staa TP, Geusens P, Pols HA, de Laet C, Leufkens HG, Cooper C. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM. 2005;98(3):191–8.PubMedCrossRef
24.
Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346–55.PubMedCrossRef
25.
• Karras D, Stoykov I, Lems WF, et al. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study. J Rheumatol. 2012;39(3):600–9. Study evaluating the effect of teriparatide in women with GIOP.
26.
• Gluer CC, Marin F, Ringe JD, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res. 2013;28(6):1355–68. Study comparing teriparatide with risedronate in men with GIOP.PubMedCrossRef
27.
•• Murphy DR, Smolen LJ, Klein TM, Klein RW. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC Musculoskeletal Disorders. 2012;13:213. Evaluation of the cost-effectiveness of teriparatide for the treatment of GIOP.PubMedCrossRef
28.
Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res. 2009;24(6):1110–5.PubMedCrossRef
29.
Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. The New England Journal of Medicine. 2005;353(6):566–75.PubMedCrossRef
30.
Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):503–11.PubMedCrossRef
31.
•• Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2013. Update of atypical fractures and the association with bisphosponate use.
32.
•• Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis–where do we go from here? The New England Journal of Medicine. 2012;366(22):2048–51. Reviews and comments on long-term use of bisphosphonates in the postmenopausal population, from FDA standpoint.PubMedCrossRef
33.
•• Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis–for whom and for how long? The New England Journal of Medicine. 2012;366(22):2051–3. Reviews and comments on long-term use of bisphosphonates in the postmenopausal population, from an invesigator and clinician standpoint.PubMedCrossRef
34.
•• Teitelbaum SL, Seton MP, Saag KG. Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum. 2011;63(2):325–8. Reviews and comments on long-term use of bisphosphonates in glucocorticoid induced osteoporosis.PubMedCrossRef
35.
Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res. 1992;7(9):1063–9.PubMedCrossRef
36.
Mok CC, Ying KY, To CH, et al. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis. 2011;70(5):778–84.PubMedCrossRef
37.
Rodriguez-Tolra J, Torremade J, di Gregorio S, Del Rio L, Franco E. Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome. Andrology. 2013;1(4):570–5.PubMedCrossRef
38.
Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–59.PubMedCrossRef
39.
McNicholl DM, Heaney LG. The safety of bisphosphonate use in pre-menopausal women on corticosteroids. Curr Drug Saf. 2010;5(2):182–7.PubMedCrossRef
40.
Langdahl BL, Marin F, Shane E, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int. 2009;20(12):2095–104.PubMedCrossRef
41.
Cohen A, Stein EM, Recker RR, et al. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study. J Clin Endocrinol Metab. 2013;98(5):1971–81.PubMedCrossRef
42.
Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20(12):2105–15.PubMedCrossRef
43.
Cha YJ, Lee YJ. Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid. Int J Clin Pharmacol Ther. 2013;51(4):274–82.PubMedCrossRef
44.
Cejka D, Haas M. Should teriparatide ever be used for adynamic bone disease? Semin Dial. 2011;24(4):431–3.PubMedCrossRef
45.
Cejka D, Kodras K, Bader T, Haas M. Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH(1-34)): a pilot study. Kidney Blood Press Res. 2010;33(3):221–6.PubMedCrossRef
46.
Chantler IW, Davie MW, Evans SF, Rees JS. Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service. Ann Rheum Dis. 2003;62(4):350–2.PubMedCrossRef
47.
Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ (Clinical research ed.). 1996; 313(7053):344–346.
48.
Curtis JR, Westfall AO, Allison JJ, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum. 2005;52(8):2485–94.PubMedCrossRef
49.
Mudano A, Allison J, Hill J, Rothermel T, Saag K. Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. J Rheumatol. 2001;28(6):1298–305.PubMed
50.
Majumdar SR, Lix LM, Yogendran M, Morin SN, Metge CJ, Leslie WD. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998–2008). J Clin Endocrinol Metab. 2012;97(4):1236–42.PubMedCrossRef
51.
Solomon DH, Katz JN, La Tourette AM, Coblyn JS. Multifaceted intervention to improve rheumatologists' management of glucocorticoid-induced osteoporosis: a randomized controlled trial. Arthritis Rheum. 2004;51(3):383–7.PubMedCrossRef
52.
Curtis JR, Westfall AO, Allison J, et al. Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial. Arch Intern Med. 2007;167(6):591–6.PubMedCrossRef
53.
Warriner AH, Outman RC, Markward NJ, et al. A web-based intervention aimed to improve bone health among individuals on chronic glucocorticoids. Arthritis Rheum. 2012;64 (Suppl 10):1978.
54.
Chitre MM, Hayes W. 3-year results of a member and physician intervention to reduce risk associated with glucocorticoid-induced osteoporosis in a health plan. J Manag Care Pharm. 2008;14(3):281–90.PubMed
Metadata
Title
Prevention and Treatment of Bone Changes Associated with Exposure to Glucocorticoids
Authors
Amy H. Warriner
Kenneth G. Saag
Publication date
01-12-2013
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 4/2013
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-013-0173-0

Other articles of this Issue 4/2013

Current Osteoporosis Reports 4/2013 Go to the issue

Osteoporosis and Cancer (P Taxel, Section Editor)

Skeletal Manifestations of Treatment of Breast Cancer

Osteoporosis and Cancer (P Taxel, Section Editor)

Osteoporosis after Stem Cell Transplantation

Epidemiology and Pathophysiology (RA Adler, Section Editor)

Evaluation and Management of the Premenopausal Woman with Low BMD

The Why and How of Fracture Liaison Services (SL Silverman, Section Editor)

Invited Commentary: Fracture Follow-Up Program in an Open Healthcare System

Hot Topic

Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs as Therapies for Osteoporosis

Quality of Care in Osteoporosis (SL Silverman, Section Editor)

National Bone Health Alliance: An Innovative Public-Private Partnership Improving America’s Bone Health